{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:50Z","timestamp":1791559430916,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05798-5","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:00Z","timestamp":1790217360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-marketing safety profile of Myfembree in approved gynecologic indications: a disproportionality analysis based on the FAERS database"],"prefix":"10.1007","author":[{"given":"Xinyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"1","key":"5798_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1089\/whr.2025.0013","volume":"6","author":"DA Aase","year":"2025","unstructured":"Aase DA, Stewart EA (2025) Use of oral gonadotropin releasing hormone antagonist combinations for preoperative management of refractory leiomyoma-related heavy menstrual bleeding. Womens Health Rep (New Rochelle) 6(1):341\u2013343. https:\/\/doi.org\/10.1089\/whr.2025.0013","journal-title":"Womens Health Rep (New Rochelle)"},{"issue":"7","key":"5798_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJMoa2008283","volume":"384","author":"A Al-Hendy","year":"2021","unstructured":"Al-Hendy A, Lukes AS, Poindexter AN 3rd et al (2021) Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med 384(7):630\u2013642. https:\/\/doi.org\/10.1056\/NEJMoa2008283","journal-title":"N Engl J Med"},{"issue":"4","key":"5798_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/14656566.2022.2030705","volume":"23","author":"M Ali","year":"2022","unstructured":"Ali M, Chen HY, Chiang YF, Badary OA, Hsia SM, Al-Hendy A (2022) An evaluation of relugolix\/estradiol\/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother 23(4):421\u2013429. https:\/\/doi.org\/10.1080\/14656566.2022.2030705","journal-title":"Expert Opin Pharmacother"},{"issue":"2 Suppl","key":"5798_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.xfre.2022.11.010","volume":"4","author":"JC Arjona Ferreira","year":"2023","unstructured":"Arjona Ferreira JC, Migoya E (2023) Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis. F S Rep 4(2 Suppl):73\u201382. https:\/\/doi.org\/10.1016\/j.xfre.2022.11.010","journal-title":"F S Rep"},{"issue":"1","key":"5798_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jama.2025.2975","volume":"334","author":"S As-Sanie","year":"2025","unstructured":"As-Sanie S, Mackenzie SC, Morrison L et al (2025) Endometriosis: a review. JAMA 334(1):64\u201378. https:\/\/doi.org\/10.1001\/jama.2025.2975","journal-title":"JAMA"},{"key":"5798_CR6","doi-asserted-by":"publisher","unstructured":"Billone V, Gullo G, Conti E et al (2025) Minilaparoscopic versus conventional laparoscopic hysterectomy: insights from a single-center retrospective cohort study with legal considerations. Medicina (Kaunas) 61(7). https:\/\/doi.org\/10.3390\/medicina61071216","DOI":"10.3390\/medicina61071216"},{"issue":"4","key":"5798_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40265-024-02018-3","volume":"84","author":"HA Blair","year":"2024","unstructured":"Blair HA (2024) Relugolix\/estradiol\/norethisterone acetate: a review in endometriosis-associated pain. Drugs 84(4):449\u2013457. https:\/\/doi.org\/10.1007\/s40265-024-02018-3","journal-title":"Drugs"},{"issue":"4","key":"5798_CR8","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1152\/physrev.00010.2024","volume":"105","author":"SE Bulun","year":"2025","unstructured":"Bulun SE, Yin P, Wei J et al (2025) Uterine fibroids. Physiol Rev 105(4):1947\u20131988. https:\/\/doi.org\/10.1152\/physrev.00010.2024","journal-title":"Physiol Rev"},{"key":"5798_CR9","doi-asserted-by":"publisher","unstructured":"Carballo Garcia A, Fernandez Risquez AC, Delgado Garcia S, Romero Duarte P, Presa Lorite JC (2025) Relugolix in monotherapy and combined therapy for the treatment of uterine diseases and its effects on bones: a systematic review. Biomedicines 13(8). https:\/\/doi.org\/10.3390\/biomedicines13081851","DOI":"10.3390\/biomedicines13081851"},{"key":"5798_CR10","doi-asserted-by":"publisher","unstructured":"Chitoran E, Rotaru V, Gelal A et al (2025) Using artificial intelligence to develop clinical decision support systems-the evolving road of personalized oncologic therapy. Diagnostics (Basel) 15(18). https:\/\/doi.org\/10.3390\/diagnostics15182391","DOI":"10.3390\/diagnostics15182391"},{"key":"5798_CR11","doi-asserted-by":"publisher","unstructured":"Cucinella G, Gullo G, Catania E et al (2024) Stem cells and infertility: a review of clinical applications and legal frameworks. J Pers Med 14(2). https:\/\/doi.org\/10.3390\/jpm14020135","DOI":"10.3390\/jpm14020135"},{"key":"5798_CR12","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2023","unstructured":"Cutroneo PM, Sartori D, Tuccori M et al (2023) Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul 3:1323057. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057","journal-title":"Front Drug Saf Regul"},{"issue":"2","key":"5798_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/bcp.15897","volume":"90","author":"ME de Lange","year":"2024","unstructured":"de Lange ME, Semmler A, Clark TJ et al (2024) Considerations on implementation of the newest treatment for symptomatic uterine fibroids: oral GnRH antagonists. Br J Clin Pharmacol 90(2):392\u2013405. https:\/\/doi.org\/10.1111\/bcp.15897","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"5798_CR14","doi-asserted-by":"publisher","DOI":"10.1515\/med-2025-1144","volume":"20","author":"L De Paola","year":"2025","unstructured":"De Paola L, Napoletano G, Gullo G, Circosta F, Montanari Vergallo G, Marinelli S (2025) The era of increasing cancer survivorship: trends in fertility preservation, medico-legal implications, and ethical challenges. Open Med (Wars) 20(1):20251144. https:\/\/doi.org\/10.1515\/med-2025-1144","journal-title":"Open Med (Wars)"},{"key":"5798_CR15","doi-asserted-by":"publisher","unstructured":"Douxfils J, Didembourg M, Maitrot-Mantelet L et al (2026) Venous thromboembolism risk associated with relugolix-estradiol-norethisterone acetate combination therapy. J Endocr Soc 10(2):bvaf190. https:\/\/doi.org\/10.1210\/jendso\/bvaf190","DOI":"10.1210\/jendso\/bvaf190"},{"issue":"Suppl 2","key":"5798_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12919-023-00285-8","volume":"18","author":"P Fernainy","year":"2024","unstructured":"Fernainy P, Cohen AA, Murray E, Losina E, Lamontagne F, Sourial N (2024) Rethinking the pros and cons of randomized controlled trials and observational studies in the era of big data and advanced methods: a panel discussion. BMC Proc 18(Suppl 2):1. https:\/\/doi.org\/10.1186\/s12919-023-00285-8","journal-title":"BMC Proc"},{"key":"5798_CR17","doi-asserted-by":"publisher","DOI":"10.2174\/0115734048466896260519070015","author":"PE Ferrara","year":"2026","unstructured":"Ferrara PE, Calciano R, Cutaia A et al (2026) Current perspectives on the prevention of secondary lymphedema in women with gynecologic cancers: a narrative review. Curr Womens Health Rev. https:\/\/doi.org\/10.2174\/0115734048466896260519070015","journal-title":"Curr Womens Health Rev"},{"key":"5798_CR18","doi-asserted-by":"publisher","unstructured":"Gullo G, Perino A, Cucinella G (2022a) Open vs. closed vitrification system: which one is safer? Eur Rev Med Pharmacol Sci 26(4):1065\u20131067. https:\/\/doi.org\/10.26355\/eurrev_202202_28092","DOI":"10.26355\/eurrev_202202_28092"},{"key":"5798_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58091218","author":"G Gullo","year":"2022","unstructured":"Gullo G, Scaglione M, Cucinella G et al (2022b) Neonatal outcomes and long-term follow-up of children born from frozen embryo, a narrative review of latest research findings. Medicina (Kaunas). https:\/\/doi.org\/10.3390\/medicina58091218","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"5798_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312481","volume":"19","author":"R Li","year":"2024","unstructured":"Li R, Chen X, Wang Y (2024) Adverse events analysis of relugolix (Orgovyx(R)) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS). PLoS One 19(10):e0312481. https:\/\/doi.org\/10.1371\/journal.pone.0312481","journal-title":"PLoS One"},{"key":"5798_CR21","doi-asserted-by":"publisher","unstructured":"Margioula-Siarkou C, Almperis A, Gullo G et al (2023) Sentinel lymph node staging in early-stage cervical cancer: a comprehensive review. J Clin Med 13(1). https:\/\/doi.org\/10.3390\/jcm13010027","DOI":"10.3390\/jcm13010027"},{"key":"5798_CR22","doi-asserted-by":"publisher","unstructured":"Moise A, Dzeitova M, de Landsheere L, Nisolle M, Brichant G (2025) Endometriosis and infertility: gynecological examination practical guide. J Clin Med 14(6). https:\/\/doi.org\/10.3390\/jcm14061904","DOI":"10.3390\/jcm14061904"},{"issue":"5","key":"5798_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/AOG.0000000000005145","volume":"141","author":"MF Neblett","year":"2023","unstructured":"Neblett MF 2nd, Stewart EA (2023) Oral gonadotropin-releasing hormone antagonists for the treatment of uterine leiomyomas. Obstet Gynecol 141(5):901\u2013910. https:\/\/doi.org\/10.1097\/AOG.0000000000005145","journal-title":"Obstet Gynecol"},{"key":"5798_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/IJWH.S442357","volume":"16","author":"ER Othman","year":"2024","unstructured":"Othman ER, Al-Hendy A, Mostafa R, Lambalk CB, Mijatovic V (2024) Oral GnRH antagonists in combination with estradiol and norethindrone acetate for pain relief associated with endometriosis: a review of evidence of a novel class of hormonal agents. Int J Womens Health 16:309\u2013321. https:\/\/doi.org\/10.2147\/IJWH.S442357","journal-title":"Int J Womens Health"},{"key":"5798_CR25","doi-asserted-by":"publisher","unstructured":"Piergentili R, Gullo G, Basile G et al (2023) Circulating miRNAs as a tool for early diagnosis of endometrial cancer-implications for the fertility-sparing process: clinical, biological, and legal aspects. Int J Mol Sci 24(14). https:\/\/doi.org\/10.3390\/ijms241411356","DOI":"10.3390\/ijms241411356"},{"key":"5798_CR26","doi-asserted-by":"publisher","unstructured":"Piergentili R, Marinelli E, De Paola L et al (2025) Epigenetics of endometrial cancer: the role of chromatin modifications and medicolegal implications. Int J Mol Sci 26(15). https:\/\/doi.org\/10.3390\/ijms26157306","DOI":"10.3390\/ijms26157306"},{"issue":"3","key":"5798_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1515\/oncologie-2025-0480","volume":"28","author":"RA Pugliesi","year":"2026","unstructured":"Pugliesi RA, Ben Mansour K, Gullo G et al (2026a) CT-based radiomics in ovarian and endometrial cancers: toward predictive biomarkers for targeted therapy. Oncologie 28(3):513\u2013521. https:\/\/doi.org\/10.1515\/oncologie-2025-0480","journal-title":"Oncologie"},{"key":"5798_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2026.102444","volume":"66","author":"RA Pugliesi","year":"2026","unstructured":"Pugliesi RA, Mansour KB, Apitzsch J et al (2026b) Diagnostic value of diffusion-weighted MRI as an imaging biomarker for ovarian cancer: a systematic review and meta-analysis. Surg Oncol 66:102444. https:\/\/doi.org\/10.1016\/j.suronc.2026.102444","journal-title":"Surg Oncol"},{"key":"5798_CR29","doi-asserted-by":"publisher","unstructured":"Rotaru V, Chitoran E, Gelal A, Gullo G, Stefan DC, Simion L (2025) Living after pelvic exenteration: a mixed-methods synthesis of quality-of-life outcomes and patient perspectives. J Clin Med 14(18). https:\/\/doi.org\/10.3390\/jcm14186541","DOI":"10.3390\/jcm14186541"},{"issue":"1","key":"5798_CR30","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/hematology.2024000591","volume":"2024","author":"L Skeith","year":"2024","unstructured":"Skeith L, Bates SM (2024) Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices. Hematology 2024(1):644\u2013651. https:\/\/doi.org\/10.1182\/hematology.2024000591","journal-title":"Hematology"},{"key":"5798_CR31","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.2147\/DDDT.S373546","volume":"17","author":"T Tatenuma","year":"2023","unstructured":"Tatenuma T, Miyamoto H (2023) Profile of relugolix in the management of advanced hormone-sensitive prostate cancer: design, development, and place in therapy. Drug des Devel Ther 17:2325\u20132333. https:\/\/doi.org\/10.2147\/DDDT.S373546","journal-title":"Drug des Devel Ther"},{"issue":"1","key":"5798_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.fertnstert.2024.04.041","volume":"122","author":"S Vannuccini","year":"2024","unstructured":"Vannuccini S, Petraglia F, Carmona F, Calaf J, Chapron C (2024) The modern management of uterine fibroids-related abnormal uterine bleeding. Fertil Steril 122(1):20\u201330. https:\/\/doi.org\/10.1016\/j.fertnstert.2024.04.041","journal-title":"Fertil Steril"},{"key":"5798_CR33","doi-asserted-by":"publisher","unstructured":"Wright D, Kim JW, Lindsay H, Catherino WH (2023) A review of GnRH antagonists as treatment for abnormal uterine bleeding-leiomyoma (AUB-L) and their influence on the readiness of service members. Mil Med 188(7\u20138). https:\/\/doi.org\/10.1093\/milmed\/usac078","DOI":"10.1093\/milmed\/usac078"},{"issue":"17","key":"5798_CR34","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2217\/fon-2023-0658","volume":"20","author":"H Zhang","year":"2024","unstructured":"Zhang H, Lu X, Lu B, Gullo G, Chen L (2024) Measuring the composition of the tumor microenvironment with transcriptome analysis: past, present and future. Future Oncol 20(17):1207\u20131220. https:\/\/doi.org\/10.2217\/fon-2023-0658","journal-title":"Future Oncol"},{"issue":"Suppl 1","key":"5798_CR35","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/BOT.0000000000002037","volume":"35","author":"R Zura","year":"2021","unstructured":"Zura R, Irwin DE, Mack CD, Aldridge ML, Mackowiak JI (2021) Real-world evidence: a primer. J Orthop Trauma 35(Suppl 1):S1\u2013S5. https:\/\/doi.org\/10.1097\/BOT.0000000000002037","journal-title":"J Orthop Trauma"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05798-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05798-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05798-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:02Z","timestamp":1790217362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05798-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":35,"alternative-id":["5798"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05798-5","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was based on the US Food and Drug Administration Adverse Event Reporting System (FAERS), a publicly available and deidentified pharmacovigilance database. Because no identifiable personal information was involved and no direct contact with human participants occurred, institutional review board approval and informed consent were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}